Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Infusion site extravasation? 45 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Infusion site extravasation have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.1% of all adverse event reports for PEMBROLIZUMAB.

45
Reports of Infusion site extravasation with PEMBROLIZUMAB
0.1%
of all PEMBROLIZUMAB reports
3
Deaths
7
Hospitalizations

How Dangerous Is Infusion site extravasation From PEMBROLIZUMAB?

Of the 45 reports, 3 (6.7%) resulted in death, 7 (15.6%) required hospitalization, and 1 (2.2%) were considered life-threatening.

Is Infusion site extravasation Listed in the Official Label?

Yes, Infusion site extravasation is listed as a known adverse reaction in the official FDA drug label for PEMBROLIZUMAB.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Infusion site extravasation?

HUMAN IMMUNOGLOBULIN G (822) INFLIXIMAB (435) INFLIXIMAB-DYYB (328) TREPROSTINIL (256) VEDOLIZUMAB (199) HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN (185) REMDESIVIR (144) FERRIC CARBOXYMALTOSE (118) RITUXIMAB (82) NATALIZUMAB (70)

Which PEMBROLIZUMAB Alternatives Have Lower Infusion site extravasation Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Infusion site extravasation Reports All Drugs Causing Infusion site extravasation PEMBROLIZUMAB Demographics